

# Samuel Charles Fehling, PhD

☎ ( ) - | 📍 Hoover, Alabama | 🌐 career.nerdyspace.net | ✉ sfehling@nerdyspace.net

## Professional Profile

- Detail-oriented biomedical scientist with 10+ years' experience designing and executing preclinical studies for rare diseases and molecular diagnostics.
- Skilled in pharmacological evaluation, protocol development & cross-functional preclinical coordination.

## Education

**University of Alabama at Birmingham** – Ph.D., Biomedical Sciences, December 2019 📍 Birmingham, AL

**University of Wisconsin – Eau Claire** – B.S., Biochemistry & Molecular Biology, May 2014 📍 Eau Claire, WI

## Work Experience

### **BioCryst Pharmaceuticals Inc.**

#### **Sr. Research Biologist**

2025 – Present

- Designed, validated, and executed *in vitro* studies to assess pharmacological properties and efficacy of small-molecule drug candidates in preclinical models.
- Coordinate cross-functional efforts with Chemistry, BioAnalytical, and Drug Development teams to align on project goals.

#### **Research Biologist**

2022 – 2025

- Design, validate and conduct *in vitro* biological and immunological assays for the pharmacological characterization of new small molecule drug candidates.
- Design & conduct *in vivo* studies for evaluating new drug candidates and current investigational drugs for efficacy in disease models & pharmacokinetics in rodents.

### **BioGX Inc.**

#### **Research & Development Scientist**

2020 – 2022

- Developed molecular diagnostic assays for custom order & FDA EUA-approved products.
- Assisted in developing new product lines, product platform conversions & a new PCR platform.
- Experienced in PCR platforms including BD MAX, QuantStudio, Bio-Rad CFX & ABI 7500.
- Improved upon current procedures & approaches to save development down-time & money spent.

### **University of Alabama at Birmingham (UAB)**

#### **Graduate Research Assistant**

2014 – 2019

- Developed & analyzed therapeutic drug combinations targeting liver cancer (cholangiocarcinoma).
- Established and characterized chemotherapeutic-resistant liver cancer models using innovative *in vitro* and *in vivo* techniques.
- Skilled in handling athymic nude and C57BL/6 mice, performing oral gavage, intraperitoneal injections, and managing patient-derived xenograft (PDX) models.

## Selected Publications

Aubrey L. Miller, Patrick L. Garcia, **Samuel C. Fehling**, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert CAM van Waardenburg, Karina J. Yoon (2021). *The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer*. *Cancers*.

**Samuel C. Fehling**, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon (2019). *The Combination of BET and PARP Inhibitors is Synergistic in Models of Cholangiocarcinoma*. *Cancer Letters*.